WRF
PTCT icon

Waddell & Reed Financial’s PTC Therapeutics PTCT Stock Holding History

Waddell & Reed Financial’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-11,700
Closed -$27K – 626
2015
Q4 		$27K Buy
+11,700
New +$344K ﹤0.01% 615

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Waddell & Reed Financial's PTCT Position: Q3 2020 in Review

Waddell & Reed Financial sold out of PTC Therapeutics (PTCT) in Q3 2020, closing a stake of 116,518 shares — an estimated $5.91M sold.

Waddell & Reed Financial first reported a position in PTCT in Q2 2015 and held it in 5 quarters. The position peaked at $61.2M in Q2 2015. 197 funds tracked by Wall St. Rank hold PTCT as of Q3 2020.

  • Waddell & Reed Financial reported no remaining PTC Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Waddell & Reed Financial sold 116,518 PTC Therapeutics shares in Q3 2020, an estimated $5.91M.
  • Waddell & Reed Financial first reported a position in PTC Therapeutics in Q2 2015 and held it in 5 quarters.
  • Waddell & Reed Financial's PTC Therapeutics position peaked at $61.2M in Q2 2015.
  • 197 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2020.

Based on Waddell & Reed Financial's 13F filing for Q3 2020, filed 13 Nov 2020.